The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR) was established in 1997 and since its inception has obtained over 10,000 samples procured from 4,000 consented patients at OSU. The LTBSR successfully facilitates translation of basic research in leukemia to the clinical setting by making available an extensive repository of tissue samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. The infrastructure of the OSUCCC LTBSR is supported by outstanding institutional support and is directed by Dr. Guido Marcucci, a physician-scientist and an established senior investigator in translational research in leukemia. He oversees a highly-trained staff with extensive experience in leukemia research that provides a full array of unique services to support high quality leukemia research. The LTBSR consists of a large and unique leukemia tissue repository, including both leukemic tissue and normal tissue germ line DNA, accompanied in all cases with complete pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. In addition, all the essentials of effective leukemia tissue bank management are very well-developed, including the activities of tissue collection, best practices, quality control of specimens, tissue storage, procurement of initial and follow-up samples and their pathology and clinical information, data entry and database management, and patient consent and confidentiality. The LTBSR leverages key partnerships within .the OSUCCC and efficient coordination with other key OSUCCC Shared Resources, to provide fundamental support of a key research mission of the OSUCCC: to produce high-quality basic and clinical research in hematological malignancy. While separated with regard to the mechanisms of collecting samples and allocation of samples to investigators, the LTBSR and the OSUCCC Biorepository and Biospecimen Shared Resource for solid tumors are governed by the same operational procedures with regard to commitment to the OSUCCC research mission and patients'confidentiality. The procedures for prioritizing and distributing tissue to a large base of investigators within the OSUCCC are effectively in place. The success in managing this large leukemia tissue resource is well-supported by the broad usage of this resource by >92% OSUCCC members and by high-impact publications (e.g.. Cell, Cancer Cell, Journal Clinical Oncology, Blood) by OSUCCC investigators in which the LTBSR has played a significant role.
The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR) leverages outstanding institutional support to facilitate the translation of basic research in leukemia to the clinical setting by making available an extensive repository of blood and bone marrow samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. Services provided through the LTBSR promote best practices and provide quality control of specimens from procurement to their use in high quality cancer research discovery, while maintaining patient consent and confidentiality.
|Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75|
|Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174|
|Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643|
|Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723|
|Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365|
|Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086|
|Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572|
|Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5|
|Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73|
|Madan, Esha; Parker, Taylor M; Bauer, Matthias R et al. (2018) The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 293:4262-4276|
Showing the most recent 10 out of 2602 publications